FY2024 EPS Estimates for Journey Medical Boosted by B. Riley

Journey Medical Co. (NASDAQ:DERM) – Analysts at B. Riley increased their FY2024 earnings per share (EPS) estimates for Journey Medical in a research note issued on Monday, November 18th. B. Riley analyst K. Patel now forecasts that the company will earn ($1.04) per share for the year, up from their previous forecast of ($1.13). The consensus estimate for Journey Medical’s current full-year earnings is ($0.99) per share. B. Riley also issued estimates for Journey Medical’s FY2025 earnings at ($0.61) EPS, FY2026 earnings at ($0.05) EPS, FY2027 earnings at $0.39 EPS and FY2028 earnings at $0.93 EPS.

A number of other equities research analysts have also recently commented on the company. Lake Street Capital initiated coverage on Journey Medical in a research note on Friday, September 6th. They set a “buy” rating and a $9.00 target price on the stock. Rodman & Renshaw started coverage on shares of Journey Medical in a research note on Thursday, August 22nd. They issued a “buy” rating and a $9.00 target price on the stock. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $9.38.

Journey Medical Stock Performance

Shares of Journey Medical stock opened at $5.20 on Wednesday. The business’s fifty day simple moving average is $5.64 and its 200 day simple moving average is $5.09. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 1.81. Journey Medical has a 12 month low of $2.85 and a 12 month high of $8.11. The firm has a market capitalization of $107.80 million, a P/E ratio of -5.56 and a beta of 0.92.

Institutional Trading of Journey Medical

Several institutional investors and hedge funds have recently bought and sold shares of DERM. Nwam LLC purchased a new position in shares of Journey Medical during the 3rd quarter valued at $59,000. TMD Wealth Management LLC purchased a new position in Journey Medical during the second quarter worth about $65,000. Kovitz Investment Group Partners LLC bought a new position in Journey Medical in the 3rd quarter worth about $66,000. ORG Wealth Partners LLC bought a new position in Journey Medical in the 3rd quarter worth about $110,000. Finally, Heron Bay Capital Management purchased a new stake in shares of Journey Medical in the 1st quarter valued at about $124,000. 7.25% of the stock is currently owned by hedge funds and other institutional investors.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.